3️⃣ASCENT-03/04 & TB02: Perhaps the most thought-provoking theme of #ASCO26. PFS2 is a complex endpoint. TFST and TSST may become increasingly important as we rethink treatment sequencing in the ADC era.
4️⃣REDUSE: A great reminder that impactful trials are not only about new drugs. Showing non-inferiority of q12w vs q4w denosumab could directly improve patients’ daily lives. I’d love to be involved in this kind of pragmatic research.